Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dosing

- PMLiVE

AstraZeneca’s rare disease unit receives NICE recommendation for Wolman disease therapy in infants

The enzyme replacement therapy will become the first treatment available on the NHS for the rare genetic disease

- PMLiVE

UK government and NIHR accelerate plans to improve clinical research delivery

The government has created a focused plan for action to transform UK clinical research

- PMLiVE

Innovative Trials at the 2023 Lloyds Bank British Business Excellence Awards

Innovative Trials achievements recognized at the Lloyds Bank British Business Excellence Awards

Innovative Trials

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

- PMLiVE

AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials

Evinova aims to meet the needs of patients, healthcare professionals and regulators

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

AstraZeneca gains rights to Eccogene’s cardiometabolic disease drug in deal worth over $1.8bn

The oral candidate could offer more dosing convenience over current injectable therapies

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

- PMLiVE

Innovative Trials has been shortlisted in the PMEA Awards

Innovative Trials finalist in the Support Agency of the Year at the annual PMEA industry awards.

Innovative Trials

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links